Background: Malignant mediastinal germ cell tumors are a rare disease and represent only 1% to 4% of all mediastinal tumors. Gonadal germ cell tumors are generally the most common type and constitute 90% of germ cell tumors. The mediastinum is the second most frequently affected area ahead of other extragonadal areas, which include the retroperitoneum, the sacrococcygeal area, and the central nervous system. We report on the case of a mediastinal yolk sac tumor with a complete histological response to chemotherapy. Case presentation: A 26-year-old Moroccan man, without a medical or surgical history, presented with a four-month history of chest distress, dyspnea, and a frequent dry cough for the previous month. A computed tomographic scan of the chest revealed a bulky mediastinal mass, which was biopsied. Histologically, the tumoral mass proved to be a yolk sac tumor. The serum level of alpha-fetoprotein of this patient was elevated to 19052 ng/ml. After 4 courses of preoperative chemotherapy, the patient underwent a surgical resection of the tumor, with a complete pathologic response. At the time of writing, the patient is alive with complete remission without any evidence of recurrence.
Conclusion: Primary mediastinal Yolk sac neoplasm represent a unique entity, and as such require specialized management. The diagnosis should be made not only by morphological studies but the patient's age and the elevation of serum alpha-fetoprotein should also be considered. The utilization of cisplatin-based chemotherapy is associated with the best chance of a cure for this disease. This should be followed by surgical resection of the residual tumor in the nonseminomatous germ cell tumor.
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Background Germ cell tumors of extragonadal origin represent only 1% to 5% of all germ cell tumors [1] . The mediastinum represents the most common site of extragonadal primaries (50% to 70%). More than half of mediastinal germ cell tumors are mature teratomas. Among malignant mediastinal germ cell tumors, 40% are seminomas and 60% are nonseminomatous tumors.
In spite of modern chemotherapy, the prognosis of mediastinal yolk sac tumors remains poor. The single most important prognostic indicator is whether the tumor mass can be completely excised before or after chemotherapy.
We report an extremely rare case of germ-cell tumor localized at the level of the anterior mediastinum, with a complete pathologic response after chemotherapy.
Case presentation
A 26-year-old Moroccan man, without a medical or surgical history, presented with a four-month history of chest distress, dyspnea, and a frequent dry cough for the previous month. A computed tomographic scan of the chest revealed a bulky mediastinal mass, raised moderately after contrast, measuring 10 × 12cm diameter ( Figure 1 ).
The needle core biopsy showed a malignant germ cell tumor corresponded to yolk sac tumor. The human chorionic gonadotropin levels were within normal range; but the serum level of alpha-fetoprotein of this patient was elevated to 19052 ng/ml. This supported the diagnosis of a Yolk sac tumor, a rare primary tumor within the mediastinum.
Preoperative chemotherapy included 4 cycles of BEP (cisplatin 20 mg/m 2 J1-J5; bleomycin 30 mg J2, J8, J15; etoposide 100 mg/m 2 J1-J5) was given to the patient with a partial response to chemotherapy ( Figure 2 ). The surgery was then performed based on complete excision of all residual anterior mediastinal mass with a complete pathologic response.
The patient survived 60 months after surgery with complete remission without any evidence of recurrence (Figures 3 and 4 ).
Discussion
Extragonadal germ cell tumors account for 1-5% of all germ cell tumors [1] . The most widely accepted theory suggests that extragonadal germ cell tumors arise from primordial germ cells misplaced during their migration to gonads [2] .
The mediastinum is the most common site of extragonadal germ cell tumors [3] , constituting 50-70% of all extragonadal germ cell tumors. In adults, extragonadal germ cell tumors account for 15% of primary anterior mediastinal tumors [4] .
Mediastinal nonseminomatous germ cell tumors has features that differentiate it from gonadal non seminomatous germ cell tumor, such as an association with Klinefelter syndrome and the frequent development of a hematologic malignancy [5] [6] [7] .
Mediastinal nonseminomatous germ cell tumors carry a poor prognosis with 40-50% overall survival, which classified this entity as a poor prognosis group in International Germ Cell Cancer Collaborative Group (IGCCCG) [8] [9] [10] .
Several causes of this unfavorable prognosis have been suggested, one of which is the bulky presentation that makes complete surgical resection impossible in patients with advanced-stages of the disease. The different histology of mediastinal non seminomatous germ cell tumors could also influence prognosis. Pure yolk sac and pure choriocarcinoma occur frequently among mediastinal nonseminomatous germ cell tumors but are rarely found among primary testicular tumors.
The current standard treatment in mediastinal non seminomatous germ cell tumors is chemotherapy combined with postchemotherapy residual mass excision, to achieve long-term survival.
Our case represent a rare case of mediastinal germ-cell tumor and show the importance of multidisciplinary approach which offer a good chance for patients to survive, we report in the Table 1 below the most important case report about mediastinal germ cell tumor.
Conclusion
Primary mediastinal non seminomatous germ cell tumors is a clinical and biologic entity that should be distinguished from other germ cell tumors. About 40% of these patients can envisage long-term survival with modern therapy that includes cisplatin-based chemotherapy followed by surgical resection of residual masses. Predictive factors and improvement in therapy are required for these patients.
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